Prostate cancer is the second cause of cancer related death in men. Historically, screening has consisted of serum PSA, digital rectal exams, and random US guided transrectal biopsy. Compared to older methods, mp-MRI is superior for the detection and staging of prostate cancer due to its improved visualization and lesion characterization. The PI-RADS classification system is a schema developed concordantly with mp-MRI in order to better characterize the clinical significance of imaging findings. Increasingly, mp-MRI is taking a central role in detection, staging and biopsy of prostate neoplasm. In the future it may emerge as a primary screening tool.
This abstract and the presentation materials are available to members only; a login is required.